title: Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned.
authors.affiliation: Institute of Cancer Sciences, University of Manchester, Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.
authors.forename: Corinne
authors.initials: C
authors.lastname: Faivre-Finn
authors.affiliation: St James' Institute of Oncology, Leeds, United Kingdom. Electronic address: michael.snee@leedsth.nhs.uk.
authors.forename: Michael
authors.initials: M
authors.lastname: Snee
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000628:therapy*; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000379:methods*; D017321:Clinical Trials, Phase I as Topic / Q000401:mortality; D017322:Clinical Trials, Phase II as Topic / Q000401:mortality; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D058958:Organs at Risk / Q000528:radiation effects; D012107:Research Design; D017211:Treatment Failure
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab